Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00181142 · ClinicalTrials.gov registry record · Phase 2
The Use of Daclizumab and Anti-Thymocyte Globulin in Lung Transplantation
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00181142: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT00181142 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00181142, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to compare outcomes in patients undergoing lung transplantation, using 2 different induction therapies. Primary outcome is survival and secondary outcomes include freedom from infection and freedom from rejection.
Interventions
- DRUG Zenapax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 1999-10 |
| Est. Completion | 2004-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00181142
The ClinicalTrials.gov registry entry for NCT00181142 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Zenapax is the first listed.
NCT00181142 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00181142 about?
NCT00181142 is a clinical study titled "The Use of Daclizumab and Anti-Thymocyte Globulin in Lung Transplantation". The purpose of this study is to compare outcomes in patients undergoing lung transplantation, using 2 different induction therapies. Primary outcome is survival and secondary outcomes include freedom from infection and freedom from rejection.
What is the current status of trial NCT00181142?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 1999-10. Estimated completion is 2004-12.
What interventions are being tested in trial NCT00181142?
The interventions under investigation include: Zenapax (DRUG).
Who is sponsoring clinical trial NCT00181142?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.